Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New PKU food for babies: will they like it?

NCT ID NCT04898829

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a special medical food called PKU explore in 7 infants with phenylketonuria (PKU) aged 6 months to 3 years. The goal was to see if babies would accept the product, tolerate it well, and maintain healthy phenylalanine levels and growth. The food replaced or supplemented their usual protein substitute over 28 days.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PKU explore (a special medical food for phenylketonuria)
What this could lead to
If successful, this could provide a more acceptable dietary option for managing PKU in infants, potentially improving adherence and growth outcomes.
What could go wrong
This is a very small exploratory study with only 7 participants, so results may not apply widely. It focuses on acceptability, not long-term effectiveness or safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

7 people

The number who actually took part.

Started

May 2022

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 months to 3 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * A diagnosis of PKU on new-born screening requiring a low protein diet and Phe-free L-amino acid protein substitute. * Aged between 6 months and 3 years (inclusive at screening). * Already taking part of their protein substitute in a spoonable form OR is at the stage in their PKU management when a second stage spoonable protein substitute is recommended to commence. * Well-controlled PKU, evidenced by the latest three routine blood spots being within the acceptable range, in the investigator's opinion. * Able to comply with the study protocol and take the study product, according to the opinion of the investigator. * Willingly given, written, informed consent from parents/guardian. Exclusion Criteria: * Diagnosis of persistent hyperphenylalaninaemia, or mild PKU not requiring dietary intervention with a low protein diet and Phe-free L-amino acid supplements. * Diagnosis of a concurrent condition which may adversely affect developmental progression and feeding ability. * Known milk or fish allergy/intolerance. * Patients who are currently participating in, plan to participate in or have participated in an interventional investigational drug, food or medical device trial within 30 days prior to the screening visit. * Existing significant GI issues which may affect compliance with the study protocol, according to the opinion of the investigator. * Any medical conditions precluding the study intervention, which in the opinion of the investigator may impact on metabolic control during the study period. * Use of additional macro/micronutrient supplements during the study period, unless clinically indicated and prescribed by the investigator (must be recorded in patient case record file). * Where applicable, patients NOT covered by Health Insurance System and/or not in compliance with the recommendations of National Law in force.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Phenylketonurias are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hôpital Jeanne de Flandre

    Lille, Hauts-de-France, 59037, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.